Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data
Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM), US, EU-5, Japan and China. In this report, arfolitixorin is perceived as one of the most promising pipeline drugs in CRC together with Array BioPharmas/Pfizers novel BRAF inhibitor encorafenib (Braftovi).
In US, EU and Japan, Global Data rate the launch of arfolitixorin as one of few events with major impact on the market. In the rating of the most important events the expected launch of arfolitixorin in 2023 is expected to have a significant impact of the market and perceived as a future leading brand.